Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Malignant transformation of neurocutaneous melanosis (NCM) following immunosuppression.

Literature DB >> 30868657

Malignant transformation of neurocutaneous melanosis (NCM) following immunosuppression.

Lauren R Schaff¹, Ashfaq Marghoob², Marc K Rosenblum³, Rina Meyer⁴, Yasmin Khakoo⁵.

Abstract

Neurocutaneous melanosis (NCM) is the condition of abnormal melanocyte deposition in the leptomeninges and brain parenchyma. Associated with congenital melanocytic nevi, NCM can result in neurologic deficits, hydrocephalus, and rarely, malignant transformation of cells. We present the case of a 16-year-old boy with NCM who developed malignant leptomeningeal melanoma following immunosuppression with a TNFα inhibitor. To our knowledge, this is the first reported case of a patient with known NCM undergoing malignant transformation after anti-TNF therapy for inflammatory bowel disease.

Entities: Chemical Disease Gene Species

Keywords: TNF inhibitor; immunodeficiency; melanocytic nevi; neoplasms-malignant

Mesh：

Substances：

Year: 2019 PMID： 30868657 PMCID： PMC6620153 DOI： 10.1111/pde.13804

Source DB: PubMed Journal: Pediatr Dermatol ISSN： 0736-8046 Impact factor: 1.588

15 in total

1. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration.

Authors: Peter Diak; Jeffrey Siegel; Lois La Grenade; Lauren Choi; Steven Lemery; Ann McMahon
Journal: Arthritis Rheum Date: 2010-08

2. Primary cutaneous melanoma: a complication of infliximab treatment?

Authors: I Khan; L Rahman; D B McKenna
Journal: Clin Exp Dermatol Date: 2009-01-13 Impact factor: 3.470

Review 3. Development of two primary malignant melanomas after treatment with adalimumab: a case report and review of the possible link between biological therapy with TNF-alpha antagonists and melanocytic proliferation.

Authors: A C Katoulis; A Kanelleas; G Zambacos; I Panayiotides; N G Stavrianeas
Journal: Dermatology Date: 2010-05-13 Impact factor: 5.366

4. Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi--results from the NYU-LCMN registry.

Authors: E K Hale; J Stein; L Ben-Porat; K S Panageas; M S Eichenbaum; A A Marghoob; I Osman; A W Kopf; D Polsky
Journal: Br J Dermatol Date: 2005-03 Impact factor: 9.302

5. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies.

Authors: Gregory J Fulchiero; Heather Salvaggio; Joseph J Drabick; Kevin Staveley-O'Carroll; Elizabeth M Billingsley; James G Marks; Klaus F Helm
Journal: J Am Acad Dermatol Date: 2007-05 Impact factor: 11.527

Review 6. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors: Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal: JAMA Date: 2006-05-17 Impact factor: 56.272

7. Complications of congenital melanocytic naevi in children: analysis of 16 years' experience and clinical practice.

Authors: V A Kinsler; W K Chong; S E Aylett; D J Atherton
Journal: Br J Dermatol Date: 2008-07-30 Impact factor: 9.302

8. The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model.

Authors: Nicolas Larmonier; Dominique Cathelin; Claire Larmonier; Alexandra Nicolas; Delphine Merino; Nona Janikashvili; Sylvain Audia; Andrew Bateman; Jill Thompson; Tim Kottke; Thomas Hartung; Emmanuel Katsanis; Richard Vile; Bernard Bonnotte
Journal: Exp Cell Res Date: 2007-03-30 Impact factor: 3.905